恩瑞格多少钱？

It is a common drug used clinically to treat anemia. The price of Enrig is also a concern of patients. Deferasirox (Enrego) from Novartis, Switzerland, has a specification of 400mg*30 tablets/box, and the price is about $700. The specification of deferasirox in India is 500*30 tablets/box, and the price is about $500.

Deferasirox (Enriga) is currently the only oral iron chelator developed by Novartis. It was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions. In December 2012, Deferasirox was approved by the European Commission for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy. On January 23, 2013, the FDA approved a new indication for deferasirox for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT).

The treatment of thalassemia is relatively difficult, and the cost of long-term treatment may be relatively high. Ordinary families may not be able to afford it. The conditions for hematopoietic stem cell transplantation are relatively high and the cost of surgery will be relatively high. The patient's condition does not meet the waiting conditions, so we should still actively take preventive measures in our lives.

Phase II and III clinical trials and pharmacokinetic studies have shown that Enriga has good safety and tolerability in the treatment of thalassemia (NTDT), and can significantly reduce the iron load on the heart and liver, making it easy to be accepted by patients. At the same time, Enriga also has pharmaceutical properties such as antifungal (such as Mucor that grows in an iron-rich environment), anti-cell proliferation, anti-malaria, anti-oxidative stress damage, anti-cytotoxic-induced apoptosis, etc.; it can be used for the treatment of secondary hemochromatosis, porphyria cutanea tarda and other diseases.